Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease

  • Kathleen E. Corey
    Department of Medicine, Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts
    Search for articles by this author
  • Naga Chalasani
    Reprint requests Address requests for reprints to: Naga Chalasani, MD, Professor of Medicine and Cellular and Integrative Physiology, Chief, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4100, Indianapolis, Indiana 46202; fax: (317) 278-1949.
    Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    Search for articles by this author
Published:August 19, 2013DOI:
      Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of liver disease in the United States and is associated with an increased risk of cardiovascular disease (CVD) and cardiovascular (CV) mortality, independent of traditional cardiovascular risk factors. CVD is one of the most common causes of death among individuals with NAFLD and management of NAFLD must extend beyond liver disease to include CVD risk modification. Clinicians should assess CVD risk with the Framingham Risk Score and screen for CVD risk factors including dyslipidemia, diabetes mellitus, hypertension, tobacco use, and the metabolic syndrome. CVD risk factors, particularly dyslipidemia, require aggressive medical management to reduce the high risk of CVD events and death in individuals with NAFLD.


      Abbreviations used in this paper:

      CV (cardiovascular), CVD (cardiovascular disease), DM (diabetes mellitus), FRS (Framingham Risk Score), HDL (high-density lipoprotein), HDL-C (HDL-cholesterol), LDL (low-density lipoprotein), MetS (metabolic syndrome), NAFLD (nonalcoholic fatty liver disease), NASH (nonalcoholic steatohepatitis), NCEP (National Cholesterol Education Program), OSA (obstructive sleep apnea)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Browning J.D.
        • Szczepaniak L.S.
        • Dobbins R.
        • et al.
        Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.
        Hepatology. 2004; 40: 1387-1395
        • Williams C.D.
        • Stengel J.
        • Asike M.I.
        • et al.
        Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
        Gastroenterology. 2011; 140: 124-131
        • Charlton M.
        Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain?.
        Hepatology. 2008; 47: 1431-1433
        • Musso G.
        • Gambino R.
        • Cassader M.
        • et al.
        Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.
        Ann Med. 2011; 43: 617-649
        • Dunn W.
        • Xu R.
        • Wingard D.L.
        • et al.
        Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.
        Am J Gastroenterol. 2008; 103: 2263-2271
        • DeFilippis A.P.
        • Blaha M.J.
        • Martin S.S.
        • et al.
        Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.
        Atherosclerosis. 2013; 227: 429-436
        • Toledo F.G.
        • Sniderman A.D.
        • Kelley D.E.
        Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes.
        Diabetes Care. 2006; 29: 1845-1850
        • Speliotes E.K.
        • Massaro J.M.
        • Hoffmann U.
        • et al.
        Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.
        Hepatology. 2010; 51: 1979-1987
        • Corey K.E.
        • Lai M.
        • Gelrud L.G.
        • et al.
        Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis.
        Clin Gastroenterol Hepatol. 2012; 10: 651-656
        • Robinson J.G.
        • Wang S.
        • Smith B.J.
        • et al.
        Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
        J Am Coll Cardiol. 2009; 53: 316-322
        • Arsenault B.J.
        • Rana J.S.
        • Stroes E.S.
        • et al.
        Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women.
        J Am Coll Cardiol. 2009; 55: 35-41
      1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
        Circulation. 2002; 106: 3143-3421
        • Targher G.
        • Bertolini L.
        • Rodella S.
        • et al.
        Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients.
        Diabetes Care. 2007; 30: 2119-2121
        • Adams L.A.
        • Lymp J.F.
        • St Sauver J.
        • et al.
        The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
        Gastroenterology. 2005; 129: 113-121
        • Hamaguchi M.
        • Kojima T.
        • Takeda N.
        • et al.
        The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.
        Ann Intern Med. 2005; 143: 722-728
        • Hamaguchi M.
        • Kojima T.
        • Takeda N.
        • et al.
        Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.
        World J Gastroenterol. 2007; 13: 1579-1584
        • Soderberg C.
        • Stal P.
        • Askling J.
        • et al.
        Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.
        Hepatology. 2010; 51: 595-602
        • Ekstedt M.
        • Franzen L.E.
        • Mathiesen U.L.
        • et al.
        Long-term follow-up of patients with NAFLD and elevated liver enzymes.
        Hepatology. 2006; 44: 865-873
        • Treeprasertsuk S.
        • Leverage S.
        • Adams L.A.
        • et al.
        The Framingham risk score and heart disease in nonalcoholic fatty liver disease.
        Liver Int. 2012; 32: 945-950
        • Marchesini G.
        • Bugianesi E.
        • Forlani G.
        • et al.
        Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
        Hepatology. 2003; 37: 917-923
        • Mottillo S.
        • Filion K.B.
        • Genest J.
        • et al.
        The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.
        J Am Coll Cardiol. 2010; 56: 1113-1132
        • Oda E.
        Metabolic syndrome: its history, mechanisms, and limitations.
        Acta Diabetol. 2011; 49: 89-95
        • Greenland P.
        • Alpert J.S.
        • Beller G.A.
        • et al.
        2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        Circulation. 2010; 122: e584-e636
        • O'Leary D.H.
        • Polak J.F.
        • Kronmal R.A.
        • et al.
        Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.
        N Engl J Med. 1999; 340: 14-22
        • Folsom A.R.
        • Kronmal R.A.
        • Detrano R.C.
        • et al.
        Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA).
        Arch Intern Med. 2008; 168: 1333-1339
        • Aygun C.
        • Kocaman O.
        • Sahin T.
        • et al.
        Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease.
        Dig Dis Sci. 2008; 53: 1352-1357
        • Kim D.
        • Choi S.Y.
        • Park E.H.
        • et al.
        Nonalcoholic fatty liver disease is associated with coronary artery calcification.
        Hepatology. 2012; 56: 605-613
        • Fracanzani A.L.
        • Burdick L.
        • Raselli S.
        • et al.
        Carotid artery intima-media thickness in nonalcoholic fatty liver disease.
        Am J Med. 2008; 121: 72-78
        • Kirk E.
        • Reeds D.N.
        • Finck B.N.
        • et al.
        Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.
        Gastroenterology. 2009; 136: 1552-1560
        • Tendler D.
        • Lin S.
        • Yancy Jr., W.S.
        • et al.
        The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study.
        Dig Dis Sci. 2007; 52: 589-593
        • Shai I.
        • Schwarzfuchs D.
        • Henkin Y.
        • et al.
        Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.
        N Engl J Med. 2008; 359: 229-241
        • Estruch R.
        • Ros E.
        • Salas-Salvado J.
        • et al.
        Primary prevention of cardiovascular disease with a Mediterranean diet.
        N Engl J Med. 2013; 368: 1279-1290
        • Ryan M.C.
        • Itsiopoulos C.
        • Thodis T.
        • et al.
        The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.
        J Hepatol. 2013; 59: 138-143
        • Ouyang X.
        • Cirillo P.
        • Sautin Y.
        • et al.
        Fructose consumption as a risk factor for non-alcoholic fatty liver disease.
        J Hepatol. 2008; 48: 993-999
        • Durstine J.L.
        • Grandjean P.W.
        • Cox C.A.
        • et al.
        Lipids, lipoproteins, and exercise.
        J Cardiopulm Rehabil. 2002; 22: 385-398
        • Wood P.D.
        • Haskell W.L.
        • Blair S.N.
        • et al.
        Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men.
        Metabolism. 1983; 32: 31-39
        • St George A.
        • Bauman A.
        • Johnston A.
        • et al.
        Independent effects of physical activity in patients with nonalcoholic fatty liver disease.
        Hepatology. 2009; 50: 68-76
        • Johnson N.A.
        • Sachinwalla T.
        • Walton D.W.
        • et al.
        Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.
        Hepatology. 2009; 50: 1105-1112
        • Gunji T.
        • Matsuhashi N.
        • Sato H.
        • et al.
        Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population.
        Am J Gastroenterol. 2009; 104: 2189-2195
        • Dunn W.
        • Sanyal A.J.
        • Brunt E.M.
        • et al.
        Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).
        J Hepatol. 2012; 57: 384-391
        • Botros N.
        • Concato J.
        • Mohsenin V.
        • et al.
        Obstructive sleep apnea as a risk factor for type 2 diabetes.
        Am J Med. 2009; 122: 1122-1127
        • Ip M.S.
        • Lam B.
        • Ng M.M.
        • et al.
        Obstructive sleep apnea is independently associated with insulin resistance.
        Am J Respir Crit Care Med. 2002; 165: 670-676
        • Mooe T.
        • Franklin K.A.
        • Holmstrom K.
        • et al.
        Sleep-disordered breathing and coronary artery disease: long-term prognosis.
        Am J Respir Crit Care Med. 2001; 164: 1910-1913
        • Gami A.S.
        • Howard D.E.
        • Olson E.J.
        • et al.
        Day-night pattern of sudden death in obstructive sleep apnea.
        N Engl J Med. 2005; 352: 1206-1214
        • Steiropoulos P.
        • Tsara V.
        • Nena E.
        • et al.
        Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome.
        Chest. 2007; 132: 843-851
        • Harsch I.A.
        • Schahin S.P.
        • Radespiel-Troger M.
        • et al.
        Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome.
        Am J Respir Crit Care Med. 2004; 169: 156-162
        • Savransky V.
        • Bevans S.
        • Nanayakkara A.
        • et al.
        Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver.
        Am J Physiol Gastrointest Liver Physiol. 2007; 293: G871-G877
        • Savransky V.
        • Nanayakkara A.
        • Vivero A.
        • et al.
        Chronic intermittent hypoxia predisposes to liver injury.
        Hepatology. 2007; 45: 1007-1013
        • Aron-Wisnewsky J.
        • Minville C.
        • Tordjman J.
        • et al.
        Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese.
        J Hepatol. 2012; 56: 225-233
        • Shpirer I.
        • Copel L.
        • Broide E.
        • et al.
        Continuous positive airway pressure improves sleep apnea associated fatty liver.
        Lung. 2010; 188: 301-307
        • Gaede P.
        • Vedel P.
        • Larsen N.
        • et al.
        Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
        N Engl J Med. 2003; 348: 383-393
        • Kooy A.
        • de Jager J.
        • Lehert P.
        • et al.
        Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
        Arch Intern Med. 2009; 169: 616-625
        • Athyros V.G.
        • Tziomalos K.
        • Gossios T.D.
        • et al.
        Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis.
        Lancet. 2010; 376: 1916-1922
        • Foster T.
        • Budoff M.J.
        • Saab S.
        • et al.
        Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
        Am J Gastroenterol. 2011; 106: 71-77
        • Ekstedt M.
        • Franzen L.E.
        • Mathiesen U.L.
        • et al.
        Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.
        J Hepatol. 2007; 47: 135-141
        • Hyogo H.
        • Yamagishi S.
        • Maeda S.
        • et al.
        Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-alpha-lowering property.
        Dig Liver Dis. 2012; 44: 492-496
        • Athyros V.G.
        • Mikhailidis D.P.
        • Didangelos T.P.
        • et al.
        Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
        Curr Med Res Opin. 2006; 22: 873-883
        • Nelson A.
        • Torres D.M.
        • Morgan A.E.
        • et al.
        A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
        J Clin Gastroenterol. 2009; 43: 990-994
        • El-Serag H.B.
        • Johnson M.L.
        • Hachem C.
        • et al.
        Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes.
        Gastroenterology. 2009; 136: 1601-1608
        • Vuppalanchi R.
        • Chalasani N.
        Statins for hyperlipidemia in patients with chronic liver disease: are they safe?.
        Clin Gastroenterol Hepatol. 2006; 4: 838-839
        • Vuppalanchi R.
        • Chalasani N.
        Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management.
        Hepatology. 2009; 49: 306-317
        • Chalasani N.
        Statins and hepatotoxicity: focus on patients with fatty liver.
        Hepatology. 2005; 41: 690-695
        • Cohen D.E.
        • Anania F.A.
        • Chalasani N.
        An assessment of statin safety by hepatologists.
        Am J Cardiol. 2006; 97: 77C-81C
        • Chalasani N.
        • Aljadhey H.
        • Kesterson J.
        • et al.
        Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
        Gastroenterology. 2004; 126: 1287-1292
        • Lewis J.H.
        • Mortensen M.E.
        • Zweig S.
        • et al.
        Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
        Hepatology. 2007; 46: 1453-1463
        • Wang C.
        • Harris W.S.
        • Chung M.
        • et al.
        n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review.
        Am J Clin Nutr. 2006; 84: 5-17
        • Harris W.S.
        n-3 fatty acids and serum lipoproteins: human studies.
        Am J Clin Nutr. 1997; 65: 1645S-1654S
        • Cussons A.J.
        • Watts G.F.
        • Mori T.A.
        • et al.
        Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.
        J Clin Endocrinol Metab. 2009; 94: 3842-3848
        • Spadaro L.
        • Magliocco O.
        • Spampinato D.
        • et al.
        Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease.
        Dig Liver Dis. 2008; 40: 194-199
        • Zhu F.S.
        • Liu S.
        • Chen X.M.
        • et al.
        Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia.
        World J Gastroenterol. 2008; 14: 6395-6400
        • Pierce L.R.
        • Wysowski D.K.
        • Gross T.P.
        Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
        JAMA. 1990; 264: 71-75
        • Athyros V.G.
        • Papageorgiou A.A.
        • Hatzikonstandinou H.A.
        • et al.
        Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
        Am J Cardiol. 1997; 80: 608-613
        • Fernandez-Miranda C.
        • Perez-Carreras M.
        • Colina F.
        • et al.
        A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
        Dig Liver Dis. 2008; 40: 200-205
        • Laurin J.
        • Lindor K.D.
        • Crippin J.S.
        • et al.
        Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
        Hepatology. 1996; 23: 1464-1467
        • Canner P.L.
        • Berge K.G.
        • Wenger N.K.
        • et al.
        Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
        J Am Coll Cardiol. 1986; 8: 1245-1255
        • Akdim F.
        • Tribble D.L.
        • Flaim J.D.
        • et al.
        Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia.
        Eur Heart J. 2011; 32: 2650-2659
        • Akdim F.
        • Visser M.E.
        • Tribble D.L.
        • et al.
        Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
        Am J Cardiol. 2010; 105: 1413-1419
        • Visser M.E.
        • Wagener G.
        • Baker B.F.
        • et al.
        Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.
        Eur Heart J. 2012; 33: 1142-1149
        • Cuchel M.
        • Meagher E.A.
        • du Toit Theron H.
        • et al.
        Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.
        Lancet. 2013; 381: 40-46
        • Cuchel M.
        • Bloedon L.T.
        • Szapary P.O.
        • et al.
        Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia.
        N Engl J Med. 2007; 356: 148-156
        • Haring R.
        • Volzke H.
        • Felix S.B.
        • et al.
        Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania.
        Diabetes. 2009; 58: 2027-2031
        • Schwimmer J.B.
        • Deutsch R.
        • Kahen T.
        • et al.
        Prevalence of fatty liver in children and adolescents.
        Pediatrics. 2006; 118: 1388-1393
        • Dam-Larsen S.
        • Becker U.
        • Franzmann M.B.
        • et al.
        Final results of a long-term, clinical follow-up in fatty liver patients.
        Scand J Gastroenterol. 2009; 44: 1236-1243
        • Rafiq N.
        • Bai C.
        • Fang Y.
        • et al.
        Long-term follow-up of patients with nonalcoholic fatty liver.
        Clin Gastroenterol Hepatol. 2009; 7: 234-238

      Linked Article